Envestnet Asset Management
FOLD

Envestnet Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Envestnet Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,240
Closed -$231K – 4757
2025
Q4 		$231K Sell
16,240
-54,360
-77% -$534K ﹤0.01% 4187
2025
Q3 		$556K Buy
70,600
+6,344
+10% +$45.1K ﹤0.01% 3696
2025
Q2 		$368K Sell
64,256
-122,299
-66% -$789K ﹤0.01% 3915
2025
Q1 		$1.52M Sell
186,555
-238,864
-56% -$2.21M ﹤0.01% 2912
2024
Q4 		$4.01M Buy
425,419
+7,204
+2% +$74.9K ﹤0.01% 2253
2024
Q3 		$4.47M Sell
418,215
-32,608
-7% -$355K ﹤0.01% 2170
2024
Q2 		$4.47M Buy
450,823
+16,263
+4% +$167K ﹤0.01% 2096
2024
Q1 		$5.12M Buy
434,560
+19,178
+5% +$245K ﹤0.01% 1958
2023
Q4 		$5.89M Buy
415,382
+21,654
+5% +$246K ﹤0.01% 1774
2023
Q3 		$4.79M Buy
393,728
+248,220
+171% +$3.2M ﹤0.01% 1828
2023
Q2 		$1.83M Buy
145,508
+249
+0.2% +$2.96K ﹤0.01% 2336
2023
Q1 		$1.61M Buy
145,259
+1,182
+0.8% +$14.6K ﹤0.01% 2337
2022
Q4 		$1.76M Buy
144,077
+32,256
+29% +$363K ﹤0.01% 2251
2022
Q3 		$1.17M Sell
111,821
-7,483
-6% -$83.4K ﹤0.01% 2448
2022
Q2 		$1.28M Buy
119,304
+15,506
+15% +$128K ﹤0.01% 2404
2022
Q1 		$983K Sell
103,798
-10,961
-10% -$103K ﹤0.01% 2682
2021
Q4 		$1.32M Buy
114,759
+30,381
+36% +$339K ﹤0.01% 2437
2021
Q3 		$806K Buy
84,378
+12,292
+17% +$126K ﹤0.01% 2681
2021
Q2 		$695K Sell
72,086
-20,682
-22% -$202K ﹤0.01% 2774
2021
Q1 		$917K Buy
92,768
+58,776
+173% +$910K ﹤0.01% 2454
2020
Q4 		$785K Buy
33,992
+2,119
+7% +$43.3K ﹤0.01% 2399
2020
Q3 		$450K Buy
+31,873
New +$465K ﹤0.01% 2518
2018
Q3 		– Sell
-2,130
Closed -$33K – 1729
2018
Q2 		$33K Buy
2,130
+57
+3% +$862 ﹤0.01% 2313
2018
Q1 		$31K Sell
2,073
-103
-5% -$1.57K ﹤0.01% 2276
2017
Q4 		$31K Buy
2,176
+237
+12% +$3.26K ﹤0.01% 2440
2017
Q3 		$29K Buy
+1,939
New +$25.6K ﹤0.01% 2429

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Envestnet Asset Management's FOLD Position: Q1 2026 in Review

Envestnet Asset Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 16,240 shares — an estimated $231K sold.

Envestnet Asset Management first reported a position in FOLD in Q3 2017 and held it in 26 quarters. The position peaked at $5.89M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Envestnet Asset Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Envestnet Asset Management sold 16,240 Amicus Therapeutics shares in Q1 2026, an estimated $231K.
  • Envestnet Asset Management first reported a position in Amicus Therapeutics in Q3 2017 and held it in 26 quarters.
  • Envestnet Asset Management's Amicus Therapeutics position peaked at $5.89M in Q4 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.